Skip Ribbon Commands
Skip to main content
Translate
Translate
menu iconMenu
search iconSearch

UC San Diego's Leon Thal Named to Alzheimer's Association National Board

 

December 20, 2006  |  

Leon Thal, MD Director of the Shiley-Marcos Alzheimer’s Disease Research Center at the University of California, San Diego (UCSD) School of Medicine and the Florence Riford Chair in Alzheimer’s at UCSD, has been named to the Alzheimer's Association’s National Board of Directors.

Leon Thal, MD

“The Alzheimer's Association is the premier organization in the United States representing Alzheimer’s disease patients and their families,” said Thal.  “I am delighted to have been selected to serve on the Board, and I hope to raise awareness of both research and clinical trials by my association with this important organization.”

The Alzheimer’s Association, founded in 1980, is the first and largest voluntary health organization dedicated to finding prevention methods, treatments and an eventual cure for Alzheimer’s disease.  Thal served as a member of the Alzheimer's Association Medical and Scientific Advisory Board from 1995 to 1997 and has been on the Board of the San Diego Chapter for 10 years.

He manages UCSD’s Shiley-Marcos Alzheimer’s Disease Research Center and the national Alzheimer’s Disease Cooperative Study (ADCS.)  The ADCS was recently awarded $52 million from the National Institutes of Health to conduct new clinical trials on Alzheimer’s disease.  The award is the third renewal of a cooperative agreement between the NIH’s National Institute on Aging (NIA) and UC San Diego which coordinates the consortium of nearly 70 research sites in the United States and Canada. Thal has led the ADCS since its inception in 1991.

Dr. Thal’s major research interests include genetics, behavioral studies of dementia, clinical trials in Alzheimer’s disease, biomarkers in Alzheimer’s disease and enhancement of neuronal function and regeneration.  He serves on a variety of Alzheimer’s disease councils, including the Council of Scientific Advisors for the Byrd Alzheimer’s Center and the Alzheimer’s Association Advisory Workgroup and as the senior scientific advisor for the Lou Ruvo Brain Institute in Las Vegas, Nevada.

In addition, Thal is an editorial and journal Reviewer for Neurobiology of Aging, Alzheimer’s Disease Review, the Journal of Neural Transmission, and associate editor of Alzheimer’s and Dementia.

# # #

Media Contact: Debra Kain, 619-543-6163, ddkain@ucsd.edu




Media Contact

Related News

5/1/2015
Researchers at UC San Diego School of Medicine conducted the first population-based study that characterizes the association and temporal relationship between gastrointestinal stromal tumors (GIST) an ...
5/1/2015
In proof-of-concept experiments, researchers at University of California, San Diego School of Medicine demonstrate the ability to tune medically relevant cell behaviors by manipulating a key hub in ce ...
4/30/2015
Researchers at University of California, San Diego School of Medicine report a previously unappreciated phenomenon in which the location of injury to a neuron’s communication wire in the spinal cord — ...
4/30/2015
Urinary tract infections (UTIs) are common, and widespread antibiotic resistance has led to urgent calls for new ways to combat them. Researchers at University of California, San Diego School of Medic ...
4/29/2015
Offering a potential early intervention for Alzheimer’s disease (AD), researchers at University of California, San Diego School of Medicine and Cenna Biosciences, Inc. have identified compounds that b ...
4/29/2015
A new study by researchers at the University of California, San Diego School of Medicine has identified demographic, socioeconomic and cultural factors that contribute to a major gender disparity amon ...
4/29/2015
Researchers at University of California San Diego School of Medicine report pancreatic cancer rates are highest in countries with the least amount of sunlight. Low sunlight levels were due to a combin ...
4/29/2015
Researchers at the University of California, San Diego School of Medicine report that blocking or removing immune-suppressing cells allows a special type of chemotherapy — and the immune cells it acti ...


Share This Article



Follow Us